email: mfarlow@iupui.edu
Martin
R. Farlow, MD, currently Professor
and Vice-Chairman of Research in the Department of Neurology at Indiana
University School of Medicine, Indianapolis, Indiana, has been on the faculty in
Neurology since 1983. He received his MD in 1979 from Indiana University and
went on to do his medicine internship between 1979 and 1980 and his neurology
residency from 1980-1983, both at Indiana University.
Dr.
Farlow was President of Indiana Neurological Society between 1992 and 1994 and
is a member of many other professional societies including the American Academy
of Neurology, the American Society for Neurologic Investigations and the World
Federation of Neurology Research Group on Dementia.
Dr. Farlow is director of the National Institute of Aging-sponsored Alzheimer’s Disease Center’s Clinical Core at Indiana University and currently principal investigator on numerous research programs focusing on Alzheimer’s disease.
Over
the years, Dr. Farlow has been a reviewer for numerous journals, including the Journal
of the American Medical Association, Neurology
and Continuum. He has
an extensive publication record currently listing 196 peer-reviewed scientific
reports and 236 abstracts.
1.
Farlow
M, Gracon SI,
Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of Tacrine in Alzheimer's disease.
Journal of The American Medical Association 268:2523-2529; 1992.
2.
Farlow
M, Ghetti B,
Dlouhy S, Giaccone G, Bugiani O, Tagliavini F and Wagner S.
Cerebrospinal fluid levels of amyloid ß-protein precursor are low in
Gerstmann-Sträussler-Scheinker disease, Indiana kindred.
Neurology 44:1508-1510; 1994.
3.
Farlow
MR, Lahiri DK,
Poirier J, Davignon J, Schneider L and Hui SL.
Treatment outcome of tacrine therapy depends on apolipoprotein genotype
and gender of the subjects with Alzheimer’s disease. Neurology 50(3):
669-677; 1998.
4.
Farlow
MR
and Evans RE: Pharmacologic
treatment of cognition in Alzheimer’s dementia.
Neurology, 51:1 (Suppl. 1):S36-S44; 1998.
5.
Farlow
MR, Anand
RV, Messina J, Hartman RC and Veach J. A
52-week study of the efficacy of rivastigmine in patients with mild to
moderately severe Alzheimer’s disease. European Neurology 44:236-241;
2000.